Clinical Trials Browser

Interventional × Lymphoma × Interleukin-18 × Clear all

NCT00085904 2008-10-13

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

Phase 1 Completed

Lymphoma, Neoplasms